The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Kinetics of Aquation and Anation of Ruthenium(II) Arene Anticancer Complexes, Acidity and X‐ray Structures of Aqua Adducts
Open accessAbstract
The aqua adducts of the anticancer complexes [(η 6‐X)Ru(en)Cl][PF 6] (X=biphenyl (Bip) 1, X=5,8,9,10‐tetrahydroanthracene (THA) 2, X=9,10‐dihydroanthracene (DHA) 3; en=ethylenediamime) were separated by HPLC and characterised by mass spectrometry as the products of hydrolysis in water. The X‐ray structures of the aqua complexes [(η 6‐X)Ru(en)Y][PF 6]n, X=Bip, Y=0.5 H 2 O/0.5 OH, n=1.5 (4), X=THA, Y=0.5 H 2 O/0.5 OH, n=1.5 (5 A), X=THA, Y=H 2 O, n=2 (5 B), and X=DHA, Y=H 2 O, n=2 (6), are reported. In complex 4 there is a large propeller twist of 45° of the pendant phenyl ring with respect to the coordinated phenyl ring. Although the THA ligand in 5 A and 5 B is relatively flat, the DHA ring system in 6 is markedly bent (hinge bend ca. 35°) as in the chloro complex 3 (41°). The rates of aquation of 1–3 determined by UV/Vis spectroscopy at various ionic strengths and temperatures (1.23–2.59×10−3 s−1 at 298 K, I=0.1 M) are >20× faster than that of cisplatin. The reverse, anation reactions were very rapid on addition of 100 m M NaCl (a similar concentration to that in blood plasma). The aquation and anation reactions were about two times faster for the DHA and THA complexes compared to the biphenyl complex. The hydrolysis reactions appear to occur by an associative pathway. The p Ka values of the aqua adducts were determined by 1 H NMR spectroscopy as 7.71 for 4, 8.01 for 5 and 7.89 for 6. At physiologically‐relevant concentrations (0.5–5 μ M) and temperature (310 K), the complexes will exist in blood plasma as >89 % chloro complex, whereas in the cell nucleus significant amounts (45–65 %) of the more reactive aqua adducts would be formed together with smaller amounts of the hydroxo complexes (9–25 %, pH 7.4, [Cl−]=4 m M).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WinGX suite for small-molecule single-crystal crystallography
Farrugia, L. J. (1999) · Journal of Applied Crystallography · doi:10.1107/s0021889899006020 · Cited by 18,930
An empirical correction for absorption anisotropy
Blessing, R. H. (1995) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767394005726 · Cited by 7,928
Systematic analysis of structural data as a research technique in organic chemistry
Allen, F. H., Kennard, O., & Taylor, R. (1983) · Accounts of Chemical Research · doi:10.1021/ar00089a001 · Cited by 1,036
Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
Morris, R. E., Aird, R. E., del Socorro Murdoch, P., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010051m · Cited by 787
Self-citationAird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
Self-citationAllardyce, C. S., Dyson, P. J., Ellis, D. J., & Heath, S. L. (2001) · Chemical Communications · doi:10.1039/b104021a · Cited by 495
Guo, Z., & Sadler, P. J. (1999) · Advances in Inorganic Chemistry · doi:10.1016/s0898-8838(08)60271-8 · Cited by 354
Self-citationMechanisms of Inorganic Reactions; A Study of Metal Complexes in Solution
Basola, F., Pearson, R. G., & Williams, D. D. (1959) · Journal of The Electrochemical Society · doi:10.1149/1.2427160 · Cited by 348
Dadci, L., Elias, H., Frey, U., Hoernig, A., Koelle, U., Merbach, A. E., Paulus, H., & Schneider, J. S. (1995) · Inorganic Chemistry · doi:10.1021/ic00105a048 · Cited by 208
Rapaport, I., Helm, L., Merbach, A. E., Bernhard, P., & Lüdi, A. (1988) · Inorganic Chemistry · doi:10.1021/ic00278a025 · Cited by 145
Cited by
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Self-citationMetallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Self-citationUsing coordination chemistry to design new medicines
Ronconi, L., & Sadler, P. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2006.11.017 · Cited by 608
Self-citationRecent developments in ruthenium anticancer drugs
Levina, A., Mitra, A., & Lay, P. A. (2009) · Metallomics · doi:10.1039/b904071d · Cited by 592
van Rijt, S. H., & Sadler, P. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.003 · Cited by 592
Self-citationHabtemariam, A., Melchart, M., Fernández, R., Parsons, S., Oswald, I. D. H., Parkin, A., Fabbiani, F. P. A., Davidson, J. E., Dawson, A., Aird, R. E., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060596m · Cited by 456
Self-citationAdvances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Self-citationMeier-Menches, S. M., Gerner, C., Berger, W., Hartinger, C. G., & Keppler, B. K. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00332c · Cited by 425
Alessio, E. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600986 · Cited by 388
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Brabec, V., & Nováková, O. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.05.002 · Cited by 384
Designing organometallic compounds for catalysis and therapy
Noffke, A. L., Habtemariam, A., Pizarro, A. M., & Sadler, P. J. (2012) · Chemical Communications · doi:10.1039/c2cc30678f · Cited by 370
Self-citationAdvances in the design of organometallic anticancer complexes
Zhang, P., & Sadler, P. J. (2017) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2017.03.038 · Cited by 369
Self-citationAqueous-phase asymmetric transfer hydrogenation of ketones ? a greener approach to chiral alcohols
Wu, X., & Xiao, J. (2007) · Chemical Communications · doi:10.1039/b618340a · Cited by 358
Organometallic Half-Sandwich Iridium Anticancer Complexes
Liu, Z., Habtemariam, A., Pizarro, A. M., Fletcher, S. A., Kisova, A., Vrana, O., Salassa, L., Bruijnincx, P. C. A., Clarkson, G. J., Brabec, V., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000932 · Cited by 357
Self-citationWang, F., Habtemariam, A., van der Geer, E. P. L., Fernández, R., Melchart, M., Deeth, R. J., Aird, R., Guichard, S., Fabbiani, F. P. A., Lozano-Casal, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505798102 · Cited by 308
Self-citationCatalytic organometallic anticancer complexes
Dougan, S. J., Habtemariam, A., McHale, S. E., Parsons, S., & Sadler, P. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800076105 · Cited by 303
“The Ru–Cl bond is labile, but hydrolysis is suppressed extracellularly because of the high chloride concentration, 104 mM (8).”
Self-citationTransfer hydrogenation catalysis in cells as a new approach to anticancer drug design
Soldevila-Barreda, J. J., Romero-Canelón, I., Habtemariam, A., & Sadler, P. J. (2015) · Nature Communications · doi:10.1038/ncomms7582 · Cited by 262
Self-citation
Metadata
- Authors
- Wang, F., Chen, H., Parsons, S., Oswald, I. D. H., Davidson, J. E., & Sadler, P. J.
- Venue
- Chemistry – A European Journal
- Publisher
- Wiley
- Published
- 2003-12-05
- Volume
- 9
- Issue
- 23
- Pages
- 5810-5820
- ISSN
- 0947-6539 (ISSN-L)
- 1521-3765
- OpenAlex
- W2132797346
- Cited by
- 254
- References
- 12
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.